Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Nov 22;13(11):411.
doi: 10.3390/ph13110411.

Atopic Dermatitis as a Multifactorial Skin Disorder. Can the Analysis of Pathophysiological Targets Represent the Winning Therapeutic Strategy?

Affiliations
Review

Atopic Dermatitis as a Multifactorial Skin Disorder. Can the Analysis of Pathophysiological Targets Represent the Winning Therapeutic Strategy?

Irene Magnifico et al. Pharmaceuticals (Basel). .

Abstract

Atopic dermatitis (AD) is a pathological skin condition with complex aetiological mechanisms that are difficult to fully understand. Scientific evidence suggests that of all the causes, the impairment of the skin barrier and cutaneous dysbiosis together with immunological dysfunction can be considered as the two main factors involved in this pathological skin condition. The loss of the skin barrier function is often linked to dysbiosis and immunological dysfunction, with an imbalance in the ratio between the pathogen Staphylococcus aureus and/or other microorganisms residing in the skin. The bibliographic research was conducted on PubMed, using the following keywords: 'atopic dermatitis', 'bacterial therapy', 'drug delivery system' and 'alternative therapy'. The main studies concerning microbial therapy, such as the use of bacteria and/or part thereof with microbiota transplantation, and drug delivery systems to recover skin barrier function have been summarized. The studies examined show great potential in the development of effective therapeutic strategies for AD and AD-like symptoms. Despite this promise, however, future investigative efforts should focus both on the replication of some of these studies on a larger scale, with clinical and demographic characteristics that reflect the general AD population, and on the process of standardisation, in order to produce reliable data.

Keywords: Staphylococcus aureus; atopic dermatitis; cutaneous dysbiosis; drug delivery systems; microbial therapy; skin barrier.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Weidinger S., Beck L., Bieber T., Kabashima K., Irvine A. Atopic dermatitis. Nat. Rev. Dis. Primers. 2018;4:1. doi: 10.1038/s41572-018-0001-z. - DOI - PubMed
    1. Abuabara K., Yu A., Okhovat J.P., Allen I., Langan S.M. The prevalence of atopic dermatitis beyond childhood: A systematic review and meta-analysis of longitudinal studies. Allergy. 2018;73:696–704. doi: 10.1111/all.13320. - DOI - PMC - PubMed
    1. Patel N., Feldman S.R. Management of Atopic Dermatitis. Springer; Berlin, Germany: 2017. Adherence in atopic dermatitis; pp. 139–159. - PubMed
    1. Wollenberg A., Schnopp C. Evolution of conventional therapy in atopic dermatitis. Immunol. Allergy Clin. 2010;30:351–368. doi: 10.1016/j.iac.2010.06.005. - DOI - PubMed
    1. Guttman-Yassky E., Waldman A., Ahluwalia J., Ong P.Y., Eichenfield L.F. Atopic dermatitis: Pathogenesis. Semin. Cutan. Med. Surg. 2017;36:100–103. doi: 10.12788/j.sder.2017.036. - DOI - PubMed

LinkOut - more resources